Pioglitazone failed to significantly reduce the composite outcome (all-cause death, myocardial infarction, stroke, unstable angina, coronary or peripheral revascularization, and amputation) compared to placebo, but led to a nominally significant 16% reduction in the risk of MACE [ 120 ].
← all excerpts
A Saudi Heart Association Position Statement on Cardiovascular Diseases and Diabetes Mellitus.
1
—
—